Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Wright Medical Group NV

www.wmt.com

Latest From Fumapharm AG

Deals of the Week Plays Favorites: Our Deals Of The Year Winners!

We’ve got this year’s winners for the Deals Of The Year, as well as this week’s deal news from Forest/Aptalis, Royalty Pharma, Biogen Idec/Sangamo and a string of early deals from Johnson & Johnson.

BioPharmaceutical Deals

Royalty Pharma Earns Its Profits The Slow Way

Paying cash up front to scientists, hospitals, biotechs and pharmas in exchange for their royalty stakes in successful drugs has proven profitable for Royalty Pharma. The firm has begun applying its long-term strategy to late-stage clinical candidates in addition to marketed products.

United States Deals

Financings Of The Fortnight: Why Are Royalty-Based Financings On The Rise Again?

Plus news on recent financings by Vivus, Novira Therapeutics, Theraclone Sciences and Receptos.

Business Strategies

Deals Of The Week: Mylan/Agila, UCB/Biotie, Jazz/Concert…

Elan peels off assets to attract suitors: First Biogen buys out Elan’s 50% interest in Tysabri, then Royalty Pharma maneuvers to buy out Elan.

BioPharmaceutical Deals
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register